Altimmune (NASDAQ:ALT – Get Free Report) and United Therapeutics (NASDAQ:UTHR – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, risk, institutional ownership, earnings and analyst recommendations.
Institutional & Insider Ownership
78.0% of Altimmune shares are held by institutional investors. Comparatively, 94.1% of United Therapeutics shares are held by institutional investors. 1.6% of Altimmune shares are held by company insiders. Comparatively, 8.6% of United Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Risk & Volatility
Altimmune has a beta of 0.18, indicating that its stock price is 82% less volatile than the S&P 500. Comparatively, United Therapeutics has a beta of 0.56, indicating that its stock price is 44% less volatile than the S&P 500.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Altimmune | 1 | 1 | 7 | 0 | 2.67 |
| United Therapeutics | 0 | 2 | 11 | 0 | 2.85 |
Altimmune currently has a consensus price target of $14.33, suggesting a potential upside of 328.50%. United Therapeutics has a consensus price target of $646.00, suggesting a potential upside of 30.28%. Given Altimmune’s higher probable upside, research analysts clearly believe Altimmune is more favorable than United Therapeutics.
Profitability
This table compares Altimmune and United Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Altimmune | -214,860.98% | -31.41% | -26.96% |
| United Therapeutics | 41.56% | 20.18% | 17.98% |
Earnings and Valuation
This table compares Altimmune and United Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Altimmune | $40,000.00 | 16,266.74 | -$88.09 million | ($0.78) | -4.29 |
| United Therapeutics | $3.18 billion | 6.68 | $1.33 billion | $27.95 | 17.74 |
United Therapeutics has higher revenue and earnings than Altimmune. Altimmune is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
United Therapeutics beats Altimmune on 12 of the 14 factors compared between the two stocks.
About Altimmune
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
About United Therapeutics
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
Receive News & Ratings for Altimmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Altimmune and related companies with MarketBeat.com's FREE daily email newsletter.
